Co-Diagnostics (CODX) investor relations material

Company overview and business model

• Develops, manufactures, and sells reagents for molecular diagnostic tests targeting DNA/RNA, focusing on infectious diseases and genetic traits.

• Proprietary Co-Primers® technology reduces false positives in PCR tests and enables multiplexing and SNP detection.

• Products include PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B/C, HPV, malaria, chikungunya, dengue, and Zika, with regulatory approvals in multiple regions.

• Developed a portable PCR platform for point-of-care and at-home use, pending FDA clearance, with a strategic shift to a multiplex respiratory test (ABCR) in response to market demand.

• Intellectual property portfolio includes over 20 granted or pending patents, trade secrets, and copyrights, supporting competitive pricing and margins.

Financial performance and metrics

• As of August 20, 2026, 6,981,319 shares of common stock were outstanding, with up to 10,386,043 shares assuming full warrant exercise.

• Additional outstanding options, restricted stock units, and warrants could further increase share count.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling stockholders; may receive up to $5.31 million if all New Warrants are exercised for cash.

• Any proceeds from warrant exercises will be used for working capital and general corporate purposes.